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Summary
Chronic granulomatous disease is a primary immunodefi-
ciency due to a defect in one of six subunits that make up
the nicotinamide adenine dinucleotide phosphate oxidase
complex. The most commonly defective protein, gp91phox, is
inherited in an X-linked fashion; other defects have autoso-
mal recessive inheritance. Bacterial and fungal infections are
common presentations, although inflammatory complications
are increasingly recognized as a significant cause of morbidity
and are challenging to treat. Haematopoietic stem cell trans-
plantation offers cure from the disease with improved quality
of life; overall survival in the current era is around 85%, with
most achieving long-term cure free of medication. More
recently, gene therapy is emerging as an alternative approach.
Results using gammaretroviral vectors were disappointing
with genotoxicity and loss of efficacy, but preliminary results
using lentiviral vectors are extremely encouraging.
Keywords: chronic granulomatous disease, inflammation, in-
fection, haematopoietic stem cell transplantation, gene therapy.
Chronic granulomatous disease (CGD) was first described in
1954 in children with elevated serum gamma globulin levels
who suffered from recurrent infections.1 Since then, our
understanding of the epidemiology, clinical presentation and
pathophysiology has significantly advanced. Curative treat-
ment is now available, and patients diagnosed early today
who are able to have curative treatment can expect to lead a
normal life. This review will describe the molecular basis,
clinical presentation and treatment of the disease.
Molecular genetics
Chronic granulomatous disease occurs because of defects in
the oxidative burst accompanying phagocytosis in myeloid
cells. Defects arise in one of five subunits which make up
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase, important for the catalytic conversion of oxygen to
generate oxygen free-radical superoxide (O2
), which gives
rise to H202, HOCL and hydroxyl radicals that are critical for
killing pathogenic bacteria and fungi. In the resting state,
NADPH exists as two components:
 a membrane-bound heterodimer embedded within lyso-
somal membranes, that is composed of gp91
phox and
p22phox encoded by CYBB and CYBA, respectively;
 cytosolic proteins p47phox, p67phox, and p40phox
encoded by NCF1, NCF2 and NCF4, respectively.
The most common defects in out-bred populations are in
CYBB, which is X-linked. Other defects are inherited in an auto-
somal recessive fashion and are more common in areas of high
consanguinity. CYBA encodes p22phox, which is the other mem-
brane-bound cytochrome component embedded with gp91phox
within the membrane of lysosomes. These subunits come
together with four cytosolic components, p47phox, p67phox,
p40phox. Rac2 and Rap1 are also required for activation and
assembly of the functional complex. The assembled cytochrome
is stabilised in the endoplasmic reticulum membrane by a pro-
tein, ‘essential for reactive oxygen species’ (EROS), encoded by
CYBC1. Defects in CYBC1 also cause CGD. Within the phago-
cyte lysosome, activation of NADPH oxidase leads to loss of an
electron, which is transferred to molecular oxygen, creating a
negative charge and forming superoxide. Superoxide sponta-
neously, or through superoxide dismutase, converts to hydrogen
peroxide, which reacts with superoxide anion to form a highly
reactive hydroxyl radical that converts to hypochlorous acid in
the presence of myeloperoxidase and chlorine. Phagocyte pro-
duction of these reactive oxygen species enables potassium and
proton influx into the phagolysosome, which activates granule
proteases such as cathepsin G and elastase. The proteases cause
destruction of phagocytosed microorganisms. Superoxide has a
dual role of activating lysosomal molecules to induce killing and
a direct microbicidal affect.2
Clinical presentation
CGD is estimated to affect approximately 1 in 130,000 to
250,000 live births in an out-bred population,3-5 although
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this number may be considerably higher in populations with
a high degree of consanguinity.6-8 Diagnosis tends to be at a
younger age in X-linked disease and in male patients.4,5 The
clinical presentations of patients with CGD are predomi-
nantly infectious or inflammatory (Table I). Common patho-
gens include Staphylococcus aureus, Burkholderia cepacia
complex (which is characteristic of CGD, and Burkholderia
cepacia complex bacteraemia is pathognomic), Serratia mars-
escens and Nocardia species, as well as mycobacterial species
including atypical species and BCG. Aspergillus species, par-
ticularly Aspergillus fumigatus are well recognised and are the
most common cause of death,9,10 but other fungal pathogens
are also described (Table I). Worldwide, relatively few organ-
isms are responsible for the majority of infections. Higher
than expected rates of M. Tuberculosis may be seen in CGD
patients living in TB endemic areas.11
In children, infection is the most common presentation.
Suppurative adenitis, pneumonia, liver and lung abscesses are
the most common infectious presentations.4,5 Most liver
abscesses are caused by Staphylococcus aureus. Often, there is
a significant inflammatory element associated with infection.
Successful resolution can be obtained using antimicrobial
therapy in conjunction with systemic cortico-steroids.12 A
particularly aggressive form of pneumonitis associated with
CGD, mulch pneumonitis, is a fulminant pneumonitis after
exposure to aerosolised fungal pathogens. Combination treat-
ment with anti-fungal agents and cortico-steroids has led to
successful resolution (Fig 1).13
Although infection was initially recognised as an impor-
tant presenting feature, it has been increasingly recognised
that inflammatory manifestations play a significant role in
the complications of CGD. Most common is inflammatory
bowel disease, which may mimic Crohn’s disease, although
granulomatous strictures may cause oesophageal, pyloric or
small bowel obstruction.4,5 Inflammatory lung disease is also
a feature of CGD. The presence of granulomata can be a
complicating feature, as mycobacterial infection (tuberculosis
or atypical mycobacteria) are well described.
Inflammatory complications in CGD are due to an aber-
rant response to inflammatory stimuli. Patients with CGD
are susceptible to granulomata formation, which affect any
hollow viscus, but particularly the gastrointestinal and geni-
tourinary tracts, as well as lungs.14 The exact inflammatory
pathology is poorly understood, but several pathways are
likely to contribute. Failure of clearance of phagocytosed
material is likely to be an important inflammatory stimulus.
CGD phagocytes that lack functional NADPH oxidase accu-
mulate but are unable to clear microbial material or cellular
debris, including apoptosed neutrophils, resulting in persis-
tent cell activation and exaggerated inflammation.15 Inflam-
masome activation leading to caspase-1-mediated
inflammation may be important in CGD-associated inflam-
matory response. Symptomatic CGD patients have signifi-
cantly-raised monocyte-derived IL1b—particularly in those
with colitis, but seen in all symptomatic CGD patients com-
pared to healthy controls.16 Defective autophagy may be seen
in both mice and human CGD patients, and is associated
with reactive oxygen species-independent activation of the
inflammasome and increased release of IL1b.
Indoleamine 2,3-dioxygenase may have an important role
in the exaggerated inflammation typical of CGD. p47phox
knock-out mouse mice infected with Aspergillus fumigatus
had more damaging inflammatory lung injury than the initial
infection as well as inefficient tryptophan catabolism as a
result of blocked indoleamine 2,3-dioxygenase function.17
Most cases of CGD are recognised in childhood, although
adults with CGD are increasingly being treated. Some of
these were children treated for CGD and now transitioned to
adult care,18 whereas others were only diagnosed in adult-
hood or only presented in adulthood for the first time. Infec-
tious and inflammatory complications are similar to those
seen in childhood, but are often more severe, and require
Fig 1. Lung biopsy from a patient with X-linked chronic granuloma-
tous disease presenting with mulch pneumonitis. Haematoxylin and
eosin stain of lung tissue showing dual infection with Aspergillus
fumigatus (white arrow) and angio-invasive Absidia corymbifera (blue
arrow). [Colour figure can be viewed at wileyonlinelibrary.com]
Table I. Bacterial and fungal pathogens seen in chronic granuloma-
tous disease.
Bacteria Fungi
Staphylococcus aureus Aspergillus fumigatus
Burkholderia cepacia complex Aspergillus nidulans
Haemophilus spp Other Aspergillus spp
Mycobacterium tuberculosis Candida spp
Atypical Mycobacteria spp (including BCG) Mucor spp
Nocardia spp Acremonium spp
Serratia marcescens Scedosporium spp
Klebsiella pneumoniae
Salmonella spp
Actinomyces spp
Acinetobacter spp
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intervention and hospitalisation; pulmonary and gastroin-
testinal complications are most common.9,19,20
Diagnosis
Diagnosis is confirmed by the demonstration of abnormal
NADPH oxidase activity or protein expression, an inability
of phagocytes to produce reactive oxygen species and subse-
quent identification of the specific genetic mutation. Diagno-
sis may be made before the onset of symptoms when there is
a positive family history. NADPH oxidase activity may be
assessed in a number of ways: through superoxide genera-
tion, hydrogen peroxide production or oxygen consumption.
As NADPH oxidase is inactive in resting phagocytes,
patient neutrophils are activated by a stimulus, such as phor-
bol-12-Myristate-13 Acetate, to produce reactive oxygen spe-
cies, such as hydrogen peroxide. Superoxide generation may
be measured by examining the ability of phagocytes to
reduce a known reagent—for example, nitroblue tetrazolium
(NBT) in the NBT reduction test. Nitroblue tetrazolium is a
yellow dye that is reduced to blue formazan by the superox-
ide produced by the respiratory burst. The intracellular reac-
tion result is read manually. CGD phagocytes are unable to
generate superoxide and remain yellow as they do not
reduce NBT. Normal phagocytes show the blue insoluble,
precipitate of formazan. X-linked CGD carriers demonstrate
both colours, as two populations of phagocytes are present.
Interpretation of the result is subjective and detection of X-
linked CGD carriers can be difficult as the two phagocyte
populations may not be well defined or distinct. However,
an experienced technician will be able to quantify the per-
centage of functioning neutrophils. Flow cytometry may be
used to demonstrate absence or reduction in the oxidative
burst in CGD patients and carriers. Neutrophils are isolated
and stimulated in the same manner as for the NBT reduc-
tion test. An H2O2 detecting agent such as dihydrorho-
damine (DHR)-1,2,3 is added and freely enters the cells.
DHR is oxidised by the reactive oxygen species to rho-
damine-1,2,3, which emits a fluorescent signal detected by
the flow cytometer.
Measurement of oxygen consumption is rarely used in
clinical practice as it is time-consuming and expensive, but
does provide a quantitative assessment of oxygen consump-
tion by use of an oxygen electrode.
Determining which NADPH oxidase component is defec-
tive when an abnormal oxidase burst has been recorded can
be achieved by looking at protein expression of individual
sub units. X-linked disease due to defective gp91phox may be
inferred with a positive family history of X-linked inheritance
and demonstration of a dual population of phagocytes in the
maternal carrier, as long as the genetic defect does not solely
affect germline cells. Flow cytometric analysis of intact neu-
trophils using a monoclonal antibody against NADPH oxi-
dase components may determine the presence or absence of
the protein. However, the membrane components of
NADPH oxidase, gp91phox and p22phox, stabilise each other,
so if one is absent the other is not detectable.
Genetic analysis should be performed in all cases of
CGD,21 as defining the mutation allows for certainty in diag-
nosis and more accurate genetic counselling. The analysis of
NCF1, encoding p47phox, is complicated by the presence of
pseudo-NCF1 genes either side of the NCF1 locus.
Precise genetic diagnosis may have implications within the
clinical setting. For patients undergoing HSCT from a family
donor, the donor may be accurately screened to ensure they
do not carry the defective gene, particularly if they are a
female relative and carry CYBB mutations. If gene therapy is
considered, it is imperative that there is an accurate genetic
diagnosis. The precise mutation may be used to determine
association with degree of reduction in NADPH oxidase
activity, information that can be transferred into the clinical
setting.
Conventional treatment
Prophylaxis
The main focus of conventional treatment for CGD is pre-
vention and management of infections and inflammatory
complications. Widespread antibiotic prophylaxis was intro-
duced from the 1970s;22 sulphamethoxazole-trimethoprim is
preferred because of its safety and efficacy, and because of
the intracellular action. It was effective at reducing surgical
interventions and length of hospitalisation,23 although overall
survival was not altered due to deaths from fungal infec-
tion.24 The introduction of itraconazole prophylaxis, with
particular efficacy against aspergillus species, has improved
survival as well as reducing hospitalisations.25-28 However,
resistant organisms, sub-therapeutic levels due to poor
absorption secondary to inflammatory bowel disease and
poor compliance mean that fungal infections remain a signif-
icant cause of morbidity and mortality.
The use of interferon gamma as routine prophylaxis has
been controversial. It has been adopted more widely in the
United States than it has in Europe. Early studies suggested
that it was able to enhance superoxide production at a cellular
level,29,30 although other studies failed to replicate these find-
ings.31 A multicentre study demonstrated a 70% reduction in
incidence of infections in the treated group compared to pla-
cebo, who received antibiotic prophylaxis alone,32 although
the rate of infections in an antibiotic-only treated cohort in
Europe was lower than in the interferon gamma-treated
group.33 Most benefit may be in those with splice site muta-
tions,34 and there appears to be no additional benefit in those
who receive regular antibiotic and antifungal prophylaxis.26
Treatment of infection
Aggressive and prompt use of appropriate antibiotics and
antifungals remains the most important basis of treatment of
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infections. These should be empirically directed against
organisms associated with CGD until cultures are confirmed.
A high index of suspicion for fungal infection should be
entertained if symptoms, particularly fever, persist despite
treatment. A tissue sample may be required to identify the
organism (Fig 1). Serum markers such as galactomannan are
of limited value in CGD,9 but may be more helpful if found
on a targeted broncho-alveolar lavage.35 Serial, rather than
single, samples are more likely to be useful. Voriconazole36
or posaconazole are recommended for the treatment of inva-
sive fungal infection due to Aspergillus species and other
fungi associated with CGD,37,38 but treatment should be
guided by culture and sensitivity results. Serum levels should
be measured to ensure that therapeutic levels are obtained;
bowel inflammation may make drug absorption more erratic.
Serious side effects have been reported. Photosensitivity may
be an issue with voriconazole, and skin malignancies have
been reported following prolonged use. Neurological toxicity
and periostitis have rarely been reported with long-term use,
the latter occasionally in association with hyperflourosis.
Hepatic toxicity is common with all triazoles. More rarely,
primary adrenal insufficiency due to direct inhibition of the
steroidogenesis pathway has been reported. Dual therapy is
not recommended,39 although, in reality, many physicians
may consider it when a patient is extremely sick. Surgery
may be required for complete resolution of symptoms,25,40
although, at least for patients with hepatic abscesses or
mulch pneumonitis, concomitant treatment with corticos-
teroids may avoid the need for surgery.12,13,41
The value of granulocyte infusions to treat invasive fungal
disease continues to be debated.42 There are no clinical trial
data to validate efficacy, but case reports suggest they may be
of value in treating serious bacterial and fungal infections. A
retrospective study examined 69 infusion courses in 48
patients in a non-transplant setting over a 29-year period.43
Best results were seen when granulocyte infusions com-
menced early in the disease course and when greater num-
bers of infusions were dispensed, regardless of the disease
genotype, infection site or causative agent. More than 80%
of infections improved. Adverse events including fever, rig-
ors, flushing, vomiting, irritability or agitation were reported
in less than 2% of 1,594 individual infusions. Significantly,
however, 16 patients developed allo-immunisation. This sin-
gle site study demonstrates that granulocyte infusions are
generally safe and useful. Sourcing granulocytes can be diffi-
cult. For patients in whom stem cell transplantation is an
option, allo-immunisation may complicate subsequent treat-
ment and increase the risk of rejection or prolonged neu-
tropenia.44
Surgical intervention can be an important adjuvant treat-
ment, particularly to debride invasive fungal disease, and tis-
sue samples may aid in identification of the organism and
antifungal sensitivities. The outcome of thoracic surgery in
35 CGD patients with severe pulmonary infection has been
reported,45 with a 90-day mortality of 6% and 37% mortality
at time of analysis, predominantly from pulmonary infection.
Poor prognostic features were noted, namely chest wall resec-
tion or significant intra-operative blood loss. The authors
concluded that patients requiring thoracic surgery were high-
risk and should be considered for definitive treatment follow-
ing surgery.
Anti-inflammatory treatment
Inflammatory complications, particularly colitis, are particu-
larly challenging symptoms to address in patients with CGD,
as treatment with immunosuppressive agents might increase
the risk of infection.46 Cortico-steroids do not appear to
increase the bacterial infection risk,5 although there is an
increased risk of fungal infection,47 as well as the recognized
complications of long-term use and, particularly, growth fail-
ure. Steroid-sparing agents have been used, particularly in
CGD colitis, including azathioprine and sulfasalazine.48,49
Thalidomide has also been used with some success to treat
colitis.50,51 Pioglitazone is a peroxisome proliferator-activated
receptor gamma (PPARc) agonist that is used to treat type 2
diabetes. One study demonstrated, in murine models and
human cells, that pioglitazone enhanced stimulated mito-
chondrial-derived reactive oxygen species production in cir-
culating neutrophils and blood monocytes and in neutrophils
and inflammatory macrophages recruited to inflammatory
tissues.52 It was concluded that pioglitazone may be consid-
ered as a possible new treatment strategy for CGD patients
with severe infection. A subsequent trial in a small number
of patients failed to demonstrate any clinical benefit.53
Identification of the role of pro-inflammatory cytokines in
the inflammatory process in CGD16,55 has facilitated the
adoption of targeted blockade as a focused treatment. Anti-
TNFa monoclonal antibodies have been used, usually in
association with other immunosuppressive agents, and most
usually for treatment-resistant or fistulating colitis. Infliximab
is most commonly used, but there are increased risks of
infection.46,56 Antimicrobial prophylaxis and careful monitor-
ing for possible infections are required and it is not recom-
mended for maintenance of remission in CGD. Use of
adalimumab has been reported in CGD patients with severe
refractory colitis. Treatment with the recombinant IL-1
receptor-targeted antagonist anakinra demonstrated thera-
peutic benefit in some patients with severe colitis.57 However,
other patients with severe refractory colitis experienced only
marginal or no benefit, and no long-term relief. Although
treatment was administered for at least 3 months, no signifi-
cant infectious complications were encountered, however.
There is a single case report documenting use of the IL-23
antagonist ustekinumab to treat longstanding treatment-re-
calcitrant CGD colitis. The patient demonstrated significant
symptomatic improvement, but developed a probably severe
infection requiring discontinuation of ustekinumab, after
which symptoms returned.58 Vedolizumab is a monoclonal
antibody that binds to integrin a4b7 heterodimer and blocks
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interaction of a4b7 integrin with MAdCAM-1, which pre-
vents leukocyte binding to endothelial surface and its
extravasation into inflamed tissue. It is used to treat ulcera-
tive colitis and Crohn’s disease. A case report demonstrated
efficacy in a patient with fistulating colitis.59 However, one
small study of use in 11 patients with CGD is published with
more detailed follow-up. Seven patients reported subjective
clinical improvement; but although more than half of
patients had mucosal improvement demonstrated with
interim endoscopy treatment, they failed to sustain mucosal
healing, and there was no steroid-sparing effect.
One study focused on ways to counter the defect in
autophagy and the associated inflammasome activation man-
ifest in NOX defective mononuclear phagocytes.60 Patients
with or without inflammatory manifestations had a repro-
ducible inflammatory phenotype typifyed by
 an increase in non-classic and intermediate monocytes
 a pro-inflammatory state of mononuclear phagocytes
with increased IL-1b and tumour necrosis factor alpha
(TNFa) content
 a bias of CD4+ T lymphocytes toward a TH17 pheno-
type
 an increase in IL-17A–secreting neutrophils.
Studies of mononuclear phagocytes collected from patients
with clinical inflammation, and treated in vitro with the
mechanistic target of rapamycin (mTOR) inhibitor rapamy-
cin to restore autophagy, showed reduced basal TNFa pro-
duction and secretion, suppression of IL-1b, IL-6 and IL-23
secretion by lipopolysaccharide-primed monocytes and
impaired TH17 switching. Importantly, inhibition of the IL-1
receptor with anakinra enhanced the inhibition of phagocyte
IL-1b secretion by rapamycin. Whilst these are in vitro data,
they suggest that a combination of rapamycin with anakinra
could be considered for patients with CGD with inflamma-
tory complications.
As increasing numbers of biological treatments become
available, studies are required to delineate which agents, and
in which combinations, lead to infection-free clinical benefit.
Stem cell therapies
Haematopoietic STEM CELL transplantation
The introduction of prophylaxis leads to improved outcomes.
A cohort of 21 children, followed for a decade at a single
centre of excellence, documented no fungal infections or
deaths and acceptable growth.61 Nonetheless, although con-
ventional and new biological treatments are improving the
mortality risk for patients with CGD, fungal infection
remains an important cause of mortality and morbidity,3 and
the fundamental problem of genetically-defective
haematopoietic stem cells persists. Patients remain at risk of
developing life-threatening infection or inflammation as they
age.5,9 In the UK cohort study, patients were frequently
hospitalised and required surgery every 45 years. Further-
more, complications were more common after the diagnosis
of CGD was made. Cumulative survival was 88% by
10 years, 73% by 20 years and 55% by 35 years of age.5
Haematopoietic stem cell transplantation (HSCT) for
patients with CGD began in the early 1970s, but was spo-
radic and considered experimental.62-66 Although CGD is a
life-threatening and potentially life-limiting primary immun-
odeficiency, the decision to take a patient with CGD to
transplant is not straightforward. Early experiences of rejec-
tion and graft failure demonstrated the need for significant
pre-transplant cytoreductive chemo-conditioning and
immunosuppression to reduce the risk of rejection. Patients
with CGD have a normal lymphocyte response and many
have hyperinflammation, increasing the likelihood of rejec-
tion. However, early full-dose busulphan/cyclophosphamide-
based conditioning regimens have significant short-term toxi-
cities (including infection, increased risk of graft versus host
disease (GvHD), veno-occlusive disease and mortality) and
long-term toxicities (including infertility). The decision on
whether to take a patient that was well on prophylaxis to a
potentially-curative transplant, but with associated toxicities
and potential mortality, was difficult for transplant physi-
cians and families. A study at the National Institutes of
Health, Bethesda, attempted to minimize these toxicities.67
Ten patients (eight with X-linked disease) aged 5–36 years
(median 15 years) received a conditioning regimen com-
prised of cyclophosphamide 60 mg/kg (on day 7 and 6),
fludarabine 25 mg/m2 (day 5 to 1) and antithymocyte
globulin (ATG) 10 mg/kg (day 5 to 2) and ciclosporin as
GvHD prophylaxis. The patients had previously experienced
two or more life-threatening infections requiring intravenous
antibiotic treatment but were infection-free at the time of
stem-cell transplantation. Donors were all HLA-identical sib-
lings and the stem cell source was G-CSF mobilized periph-
eral blood stem cells that were CD34+ selected using
magnetic beads to reduce the risk of graft versus host disease.
The reduced intensity conditioning regimen and removal of
a potential alloreactive graft versus marrow effect by donor
T-lymphocytes reduced the ease of engraftment. Nevertheless,
90% of patients engrafted, albeit with use of between one
and five donor T-lymphocyte infusions. Four patients devel-
oped grade I–IV GvHD, and two developed chronic GvHD.
At time of publication, seven were alive: one with on-going
chronic GvHD and six were well and disease-free. The three
deaths were related to infection, GvHD and complications of
a second stem cell procedure in one patient.
A multi-centre study by the European Inborn Errors
Working Party (IEWP) of ESID and EBMT reported on
transplants using myelo-ablative conditioning and an
unmodified stem cell source.68 Fourteen centres contributed
27 patients, 25 of whom were children, 23 male, 22 with X-
linked disease and one a female carrier with extreme lyonisa-
tion. Patients were grouped into those with no overt infec-
tion or inflammation (11), those with active inflammation/
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inflammatory sequalae (seven) and those with treatment-re-
fractory infection (nine) at time of transplant. Twenty-five
patients received HLA-identical matched sibling transplants,
five from heterozygous CGD carriers. Two patients (with no
overt infection or inflammation) received an HLA- identical
unrelated donor transplant. Twenty-three patients received a
busulphan-based myeloablative (16–20 mg/kg) conditioning
regimen, mostly combined with cyclophosphamide 200 mg/
kg. Lower-intensity conditioning regimens were used in four
sick patients, two with active therapy-refractory infection and
two with poor lung function.
Twenty-four patients received full, T-lymphocyte-replete
marrow innoculi, whilst three patients receiving a lower-in-
tensity conditioning regimen were given G-CSF-mobilised,
T-lymphocyte-replete peripheral blood stem cells; all patients
received ciclosporin prophylaxis. Twenty-two evaluable
patients of 23 who had received HLA-identical matched sib-
ling transplants achieved full donor chimerism; one died
before engraftment. Of four patients who received lower-in-
tensity conditioning (two bone marrow, two PBSC), two
achieved full donor chimerism and two failed to engraft. In
those with no overt infection or inflammation, one devel-
oped grade II GvHD which resolved; all had full donor chi-
merism. Of those with active inflammation/inflammatory
sequalae at time of transplant, three developed GvHD: grade
II skin that resolved (two), and grade IV gut GvHD in one
that progressed to chronic GvHD; all patients survived, with
full (six) or high level (one) donor chimerism. Of the nine
patients with treatment-refractory infection at time of trans-
plant, three developed grade II-IV acute GvHD, of whom
one died. The two survivors of acute GvHD developed
chronic GvHD. Two of the nine patients failed to engraft
and died, and one other died before engraftment. Six patients
developed full donor chimerism, of whom one died. Infec-
tions and inflammatory lesions in the five survivors resolved.
The deaths occurred in patients with pre-existing treatment-
refractory fungal infections—also the group in which the
most severe GvHD occurred. Use of myelo-ablative condi-
tioning and lymphocyte replete stem cell innoculi facilitated
complete donor chimerism and was generally well-tolerated.
In some patients, pulmonary restriction improved. The
authors concluded that excellent survival was achievable
using HLA-genoidentical donors for HSCT in patients with
active inflammation or organ dysfunction due to chronic
inflammation. Additionally, CGD patients with an HLA-
identical sibling and a history of recurrent invasive infections
or inflammatory, steroid-dependent disease, should be con-
sidered for HSCT, before irreversible organ damage arises.
A subsequent single-centre UK study examined transplant
results in 20 consecutive patients transplanted between 1998
and 2007.69 Nineteen had X-linked disease; age at transplant
ranged between 15 months and 21 years, median 75 months.
Ten received stem cells from an HLA-identical sibling (one
sibling umbilical cord blood stem cells).70 Eight patients
received 10/10 HLA-identical unrelated donor stem cells
(two PBSC, six BM); one received 9/10 HLA-matched (C
mismatch) unrelated donor PBSC; one received 9/10 HLA-
matched (A mismatch) unrelated donor umbilical cord blood
stem cells. Sixteen patients received myeloablative condition-
ing (busulphan 16 mg/kg, cyclophosphamide 200 mg/kg)
with alemtuzumab (1 mg/kg), given if an unrelated donor
was used. Two patients with active fungal infection and
restrictive pulmonary disease respectively received fludarabine
150 mg/m2, melphalan 140 mg/m2 and alemtuzumab 1 mg/
kg. One adult patient received alemtuzumab 2 mg/kg, flu-
darabine 150 mg/m2 and busulphan 8 mg/kg, whilst the
other adult patient received CAMPATH 1-G (100 mg total
dose), busulphan 16 mg/kg and melphalan 140 mg/m2. All
patients received cyclosporine as GvHD prophylaxis. Ten
patients had active inflammatory disease and two had active
fungal infection at time of transplant. Eighteen patients sur-
vived, with a follow-up of 4–117 months (median 61).
Engraftment with functioning neutrophils was observed in 19
patients. The oxidative burst became normal or ≥70% of
neutrophils in 15 patients. Two required unconditioned
boost marrow infusions from the original donor after the
first HSCT to improve falling donor chimerism. One patient
had a stable oxidative burst of 45%. Patients were able to
discontinue antimicrobial prophylaxis and there were no sig-
nificant infections beyond 3 months post-transplant. Patients
demonstrated resolution of inflammatory lung disease and
colitis and achieved catch-up growth post-transplant. One
patient from the HLA-identical sibling and one from the
unrelated donor group died; both had active fungal disease.
This study demonstrated good outcomes when using well-
matched unrelated donors, as well as matched sibling donors,
and in particular showed resolution of inflammation and
restoration of growth. Further study of the UK paediatric
CGD cohort in the modern transplant era demonstrated the
same good survival (90%) in transplanted patients and those
receiving antibacterial and antifungal prophylaxis.71 Notably,
however, those patients who received transplant for their dis-
ease had a significantly better quality of life than non-trans-
planted patients, similar to that of age-matched normal
control,72 although this finding was not replicated in a smal-
ler Italian study of 47 patients.73
Concerns about sequalae of HSCT and, in particular,
adverse events related to myeloablative chemotherapy
remained an obstacle in offering HSCT to affected families.
However, conventional reduced intensity conditioning gener-
ally lead to poor engraftment or high levels of GvHD.74,75
In a landmark multicentre study, the efficacy and safety of
a targeted sub-myeloblative busulphan-based regimen was
assessed.76,77 In this prospective study, 56 patients (34 with
X-linked disease) from 16 centres, median age 126 years,
were studied. Thirteen patients were ≥18 years (range 185–
393; median 22). Seventy-five percent of patients were high-
risk, with microbiologically-proven active infections, mainly
caused by Aspergillus spp. and autoinflammatory complica-
tions, predominantly colitis. The reduced-intensity
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conditioning regimen comprised fludarabine immunosup-
pressive chemotherapy, rabbit ATG-Fresenius or alem-
tuzumab serotherapy and low-dose or targeted busulfan,
targeting busulfan exposure to a cumulative area-under-the
curve (AUC) value of 45–65 mg/l 9 h, equivalent to 55–
75% of the full myeloablative cumulative AUC of 80–
100 mg/l 9 h. Twenty-one patients received stem cells from
HLA-identical related donors; 35 were transplanted using an
HLA-matched unrelated-donor, of which 25 were HLA-10/10
matched and 10 were HLA-9/10 matched. There were no sig-
nificant acute conditioning-related toxicities. The overall sur-
vival was 93% and event-free survival was 89% (50 of 56).
Three patients had early or late graft failure. The cumulative
incidence of grade III–IV GvHD was 4%; chronic GvHD was
7%. Stable myeloid donor chimerism (≥90%) was recorded
in 52 (93%) surviving patients. These results, using a safer
reduced intensity conditioning regimen, demonstrated excel-
lent survival in a mixed population of children and adults,
many of whom had significant CGD-related complications at
time of transplant, with durable high level donor chimerism.
Treosulfan is a water-soluble bi-functional alkylator that
has myeloablative and pronounced immunosuppressive prop-
erties, enabling stable engraftment post-transplant. It has
reduced organ toxicity compared to high-dose busulfan and
cyclophosphamide, causing less acute toxicity post-transplant.
The outcome of treosulfan-based conditioning of 70 CGD
patients from 16 centres worldwide was reported on behalf
of the ESID/EBMT-IEWP.78 Median age at transplant was
107 months (range 46–232); 66 patients were male. Fifty-six
had X-linked CGD. Sixty-four patients had high-risk criteria,
as ongoing or previous radiologically and microbiologically-
proven infection or autoinflammation. Thirteen patients
received stem cells from a 10/10 HLA-matched related
donor, whilst 56 received the transplant from a matched
unrelated donor (44 10/10 matched, 12 9/10, one 4/6 umbili-
cal cord blood cells; one received a CD3+ TCRab/CD19+
depleted haplo-identical parental transplant). Treosulfan was
the primary myeloablative agent; 66% of patients received
treosulfan, fludarabine and serotherapy with either ATG or
alemtuzumab, whilst 24 received other regimens, with 15
patients receiving treosulfan, fludarabine, thiotepa, with ATG
or alemtuzumab. The overall survival was 914%; 64 patients
were alive with a median follow-up of 34 months (13–102).
The cumulative incidence of grade III-IV GvHD was 12%.
Eight patients required second procedures, including two
boost infusions from the original donor without further con-
ditioning, three donor lymphocyte infusions and five second
transplants, giving an event free survival of 814%. Out of 64
patients where data were available, donor myeloid chimerism
was higher than 95% in 51 (80%). These results demon-
strated that use of a reduced toxicity myeloablative regimen
led to good survival and donor chimerism, although some
second procedures were needed.
A recently published multicentre retrospective study by
the EBMT/ESID IEWP documents the largest CGD
transplant cohort to date.79 The study describes 712 patients
(75% X-linked, 635 children <18 years) with CGD undergo-
ing allogeneic HSCT between 1993 and 2018; 87% of trans-
plants were after 2006. Many patients had significant disease
before transplant, including infections (68%), colitis (24%)
and liver impairment (9%). Busulphan-based conditioning
regimens were employed in 60% of patients, treosulfan-based
in 20%. Eighty percent of patients received a graft from a
matched related or unrelated donor, 20% from a mismatched
donor. Median age at transplant was 7 years (range 01–
486). Median follow-up was 45 months (range 1764–8279).
Overall survival was 857%. Older age at transplant
(P = 00001) and use of 9/10 HLA-matched donors (001)
associated with reduced survival. A trend for reduced survival
was seen in patients with pre-existing colitis (P = 0052), a
finding at variance with experience in the U.S., where 49/145
transplanted patients with CGD had inflammatory bowel dis-
ease and survival between the groups was the same.80 In the
IEWP study, the conditioning regimen did not impact overall
survival. The authors conclude that there was an excellent
outcome after HSCT for patients with CGD, and that trans-
plant should be firmly considered for younger patients, espe-
cially if there was a well-matched donor. However, a single-
centre UK study has also demonstrated excellent outcomes
using CD3+ TCRab T-lymphocyte depleted haplo-identical
donors81 (although results using post-transplant cyclophos-
phamide have not been so encouraging).82 Recent studies
documenting medical problems in carriers of X-linked
CGD83,84 have led to recommendations not to use them as
donors for CGD patients if possible. Although transplant
outcomes are best in younger patients,79,81 nevertheless, good
outcomes can be demonstrated in adolescent and adult
patients. An 82% survival was documented in 11 patients,
age 17–28 years (median 19), all of whom had significant
pre-existing infectious or inflammatory complications, using
matched, family or unrelated or one antigen mismatched
unrelated donors.85 Seven adolescents, six with high-risk dis-
ease, were successfully transplanted using reduced-toxicity
myeloablative busulfan conditioning—although one had graft
failure and was re-transplanted, and another had grade IV
skin and gut GvHD. All had full donor myeloid chimerism
and disease resolution.86
A particular group of patients in whom HSCT can be
challenging is those with McLeod phenotype (a neuroacan-
thocytosis syndrome) and X-linked CGD caused by large
deletions on the X-chromosome that encompass CYBB and
XK. XK encodes the Kx transmembrane protein, which links
to the Kell glycoprotein on erythyrocytes. The McLeod blood
phenotype is rare and characterized by reduced Kell glyco-
protein antigen expression. Patients develop an allo-immune
response following erythrocyte or granulocyte transfusions
and may develop brisk haemolysis as a consequence of
incompatible transfusions through HSCT. A French study
describes eight patients, four of whom were transplanted,
three of whom survived.87
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Today, HSCT for CGD has a high curative rate with low
mortality (Table II), although best results are found in young
patients with no pre-existing co-morbidities. It is not clear
which patients should be offered HSCT. Although residual
production of reactive oxygen species, predicted by the speci-
fic NADPH oxidase mutation, confers less severe illness and
a greater probability of long-term survival, it does not pro-
tect against inflammatory sequalae.88
Gene therapy
Given the significant risks associated with earlier transplants,
autologous gene addition therapy was developed to improve
patient outcomes. Unlike lymphocytes in patients with severe
combined immunodeficiencies, genetically-corrected neu-
trophils demonstrate no survival advantage over faulty neu-
trophils. As neutrophils survive only a few days in the
periphery, long-term production of gene-corrected neu-
trophils requires engraftment of comparatively high numbers
of gene-transduced haematopoietic stems cells, obliging the
administration of myeloablative chemotherapy prior to infu-
sion of transduced cells.89 A gamma-retroviral gene therapy
trial for CGD performed in Zurich demonstrated significant
clinical benefit early post-treatment, with clearance of life-
threatening fungal infection90 and restoration of neutrophil
extra-cellular traps.91,92 Clinical benefits did not persist, as
functioning neutrophils disappeared due to silencing of gene
expression caused by methylation of the LTR promoter ele-
ments. Unfortunately, persistent enhancer activity directed
transactivation of MDS/EVI proto-oncogenes, causing mono-
somy 7 and myelodysplasia in three patients, two of whom
died, and the third required HSCT. A fourth patient devel-
oped clonal expansion with no associated chromosomal
abnormalities and was successfully transplanted.93 Other tri-
als using retroviral vectors demonstrated transient clinical
benefit only, although no genotoxicity developed.94-96 As
with other primary immunodeficiencies, new lentiviral vec-
tors have been developed to reduce the genotoxicity risks
associated with retroviral vectors. The first multicentre study
to be published details nine high-risk patients, age 2–
27 years, with four further patients briefly noted in the dis-
cussion.97 All received busulphan AUC of 70–75 mg/l 9 h.
Eight had an oxidative burst >10% after 12 months; four
were >30%, but four had <10% oxidative burst. The mini-
mum oxidative burst required to prevent problems observed
in X-linked carriers has to be determined, although autoim-
munity appeared not to be associated with a particular %
DHR.84 Two patients died of reconstitution-related issues.
No genotoxicity events were reported, although maximum
follow-up was only 24 months. Nevertheless, these are
encouraging results. Current developments include the ‘safe
harbouring’ of integrating viral vectors into ‘safe’ genomic
regions of human haematopoietic stem cells to decrease risks
of ‘off-target’ effects using targeted insertion of a gp91phox
construct by use of an electroporated zinc finger nucleaseT
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mRNA and adenoassociated virus 6 delivery of donor con-
structs.98 Additionally, transcription activator-like effector
nucleases (TALENs) have been used to insert a myelo-speci-
fic gp91phox cassette into patient-derived induced pluripotent
stem cells (iPSCs).99 The CRISPR/Cas9 system has also been
shown to correct the genetic defect in human cells in X-
linked and autosomal recessive CGD.100-104
Conclusion
Significant progress in treatment approaches, prognosis, cure
and quality of life has been made since the first description
of CGD. Even in the early 1990s, there were successful trans-
plant outcomes using matched sibling and matched unrelated
donors, and it was concluded that, ‘[i]n selected patients use
of a MUD today seems a good option and early transplanta-
tion before the establishment of chronic bacterial and fungal
infections and organ damage would lessen the risk of reacti-
vation and decrease the severity of GvHD in the post-graft
period’, (p. 809).105 Certainly today, patients diagnosed with
CGD should be considered early on for curative stem cell
therapy. The role of gene therapy over HSCT for X-linked
CGD is less clear at present, and may be best considered for
high-risk patients, particularly if no well-matched donor is
available. The failure to obtain a normal oxidative burst is of
concern, as it may expose treated patients to symptoms expe-
rienced by X-linked carriers; therefore, lower risk patients
may be best treated by HSCT. However, more than 60 years
after ‘fatal granulomatous disease of childhood’ was first
described, curative therapy and a normal quality of life
should now be considered for most patients.
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